Role of Imatinib in Achieving Euglycemic State in Patient with GIST.

ABSTRACT

Gastrointestinal stromal tumor (GIST) are rare tumors arising from Interstitial Cells of Cajal and require immunohistochemical marker c-kit (CD 117) for diagnosis. Imatinib Mesylate is an orally administered drug which competitively inhibits tyrosine kinase associated with the KIT protein. We present a rare case report highlighting role of Imatinib Mesylate in achieving euglycemic state in patient with GIST. Imatinib Mesylate is an effective form of treatment for patients with KIT (CD 117) positive unresectable and/ or metastatic malignant GIST. Proper patient selection and adequate treatment may help in achieving euglycemic state in patient with GIST.